Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
Rhea-AI Summary
Akero Therapeutics has announced multiple presentations at the upcoming EASL Congress 2025 in Amsterdam, showcasing research on their drug efruxifermin for treating metabolic diseases. The company will present two oral presentations and one poster focusing on liver disease treatment.
The first oral presentation by Dr. Mazen Noureddin will discuss efruxifermin's impact on fibrosis improvement in patients with compensated cirrhosis due to MASH, based on a 96-week Phase 2b trial (SYMMETRY). The second oral presentation by Prof. Quentin M. Anstee will explore the alignment of non-invasive fibrosis biomarkers with AI-based qFibrosis histology in MASH trials.
Additionally, a poster presentation by Prof. Jörn M. Schattenberg will demonstrate how qFibrosis enables earlier detection of fibrosis response in efruxifermin-treated patients with F2-F3 MASH in the 96-week HARMONY study. All presentations will take place between May 7-10, 2025.
Positive
- Multiple high-profile presentations at EASL Congress 2025 demonstrate strong scientific interest in Efruxifermin
- 96-week long-term data from SYMMETRY trial showing fibrosis improvement in cirrhosis patients suggests drug efficacy
- AI-based qFibrosis analysis validates drug effectiveness through multiple measurement methods
- Early detection of fibrosis response in HARMONY study indicates potential faster treatment benefits
Negative
- None.
News Market Reaction
On the day this news was published, AKRO gained 5.97%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two oral presentations and an upcoming poster presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, 2025, in Amsterdam, the Netherlands.
Details for the presentations are as follows:
Oral presentation 1
Title: Efruxifermin improves fibrosis in participants with compensated cirrhosis due to MASH: results of a 96-week, randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)
Speaker: Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Date/Time: Friday, May 9, 2025, from 12:15 PM – 12:30 PM CET
Presentation ID: GS-012
Oral Session: General Session 2
Oral presentation 2
Title: Alignment of response assessed by non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in metabolic dysfunction associated steatohepatitis (MASH) clinical trials: a new roadmap for robust drug efficacy assessment demonstrated in the HARMONY trial
Speaker: Prof. Quentin M. Anstee, Ph.D., FRCP, Ruth & Lionel Jacobson Chair of Personalised Medicine, Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UK
Date/Time: Saturday, May 10, 2025, from 10:30 – 10:45 CET
Presentation ID: OS-096
Oral Session: MASLD: Clinical and therapeutical aspects II
Poster presentation
Title: qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study
Presenter: Jörn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of Saarland
Date/Time: Saturday, May 10, 2025, from 8:30 – 16:00 CET
Presentation ID: TOP-458
Session: Poster - MASLD: Therapy
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
Peg.rusconi@deerfieldgroup.com
FAQ
What will Akero Therapeutics (AKRO) present at EASL Congress 2025?
What are the key findings of AKRO's SYMMETRY trial presented at EASL 2025?
How does Efruxifermin affect fibrosis in MASH patients according to AKRO's HARMONY study?
When will AKRO present at EASL Congress 2025?
What non-invasive methods does AKRO use to assess Efruxifermin's effectiveness?
